A Phase 1/2 Study of Combination Osimertinib and Bevacizumab as Treatment for Patients With EGFR-mutant Lung Cancers

Trial Profile

A Phase 1/2 Study of Combination Osimertinib and Bevacizumab as Treatment for Patients With EGFR-mutant Lung Cancers

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Sep 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Osimertinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 02 Jun 2017 Results (n=15) assessing the safety, tolerability and MTD of osimertinib and bevacizumab combination in patients with advanced EGFR-mutant lung cancers, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 29 Jun 2016 Planned number of patients changed from 55 to 58.
    • 29 Jun 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top